Pioglitazone and Risk of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus. A Meta-analysis of Randomized Trials

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH 44195, USA.
JAMA The Journal of the American Medical Association (Impact Factor: 35.29). 10/2007; 298(10):1180-8. DOI: 10.1001/jama.298.10.1180
Source: PubMed


Pioglitazone is widely used for glycemic control in patients with type 2 diabetes mellitus, but evidence is mixed regarding the influence of medications of this class on cardiovascular outcomes.
To systematically evaluate the effect of pioglitazone on ischemic cardiovascular events.
A database containing individual patient-level time-to-event data collected during pioglitazone clinical trials was transferred from the drug's manufacturer for independent analysis. Trials were included if they were randomized, double-blinded, and controlled with placebo or active comparator.
The primary outcome was a composite of death, myocardial infarction, or stroke. Secondary outcome measures included the incidence of serious heart failure. A fixed-effects approach was used to combine the estimates across the duration strata and statistical heterogeneity across all the trials was tested with the I2 statistic.
A total of 19 trials enrolling 16 390 patients were analyzed. Study drug treatment duration ranged from 4 months to 3.5 years. Death, myocardial infarction, or stroke occurred in 375 of 8554 patients (4.4%) receiving pioglitazone and 450 of 7836 patients (5.7%) receiving control therapy (hazard ratio [HR], 0.82; 95% confidence interval [CI], 0.72-0.94; P = .005). Progressive separation of time-to-event curves became apparent after approximately 1 year of therapy. Individual components of the primary end point were all reduced by a similar magnitude with pioglitazone treatment, with HRs ranging from 0.80 to 0.92. Serious heart failure was reported in 200 (2.3%) of the pioglitazone-treated patients and 139 (1.8%) of the control patients (HR, 1.41; 95% CI, 1.14-1.76; P = .002). The magnitude and direction of the favorable effect of pioglitazone on ischemic events and unfavorable effect on heart failure was homogeneous across trials of different durations, for different comparators, and for patients with or without established vascular disease. There was no evidence of heterogeneity across the trials for either end point (I2 = 0%; P = .87 for the composite end point and I2 = 0%; P = .97 for heart failure).
Pioglitazone is associated with a significantly lower risk of death, myocardial infarction, or stroke among a diverse population of patients with diabetes. Serious heart failure is increased by pioglitazone, although without an associated increase in mortality.

Download full-text


Available from: Kathy Wolski, Mar 14, 2014
    • "However, fluid retention resulting in the worsening of congestive heart failure and peripheral oedema relates to class effect of TDZ, which have been shown to be mediated through the abundant PPARc receptors expressed in renal collecting ducts [31] [32]. Pioglitazone has been shown to have far less significant cardiovascular side-effects in a recent meta-analysis [33]. However , the primary concern of recent times regarding the use of pioglitazone is its association with the increased incidence of bladder cancer [34,35]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The established role of glutamate in the pathogenesis of glioma-associated seizures (GAS) led us to investigate a novel treatment method using an established drug class, peroxisome proliferator activated receptor (PPAR) gamma agonists. Previously, sulfasalazine has been shown to prevent release of glutamate from glioma cells and prevent GAS in rodent models. However, raising protein mediated glutamate transport via excitatory amino acid transporter 2 (EAAT2) has not been investigated previously to our knowledge. PPAR gamma agonists are known to upregulate functional EAAT2 expression in astrocytes and prevent excitotoxicity caused by glutamate excess. These agents are also known to have anti-neoplastic mechanisms. Herein we discuss and review the potential mechanisms of these drugs and highlight a novel potential treatment for GAS.
    Journal of Clinical Neuroscience 11/2014; 22(1). DOI:10.1016/j.jocn.2014.09.001 · 1.38 Impact Factor
  • Source
    • "Treatment with pioglitazone is associated with weight gain (4.7% in the PIVENS study)22 and there have been reports of increased risk of congestive cardiac failure,42 bladder cancer43 and reduced bone density.44 However, a meta-analysis of 16 390 patients with type 2 diabetes mellitus (T2DM) treated with pioglitazone demonstrated an 18% reduction in death, myocardial infarction and stroke.45 Therefore, after assessing risk and benefit, treatment with pioglitazone can be recommended for patients with more aggressive NASH who have failed lifestyle interventions.46 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Non-alcoholic fatty liver disease (NAFLD) affects up to a third of the population in many developed countries. Between 10% and 30% of patients with NAFLD have non-alcoholic steatohepatitis (NASH) that can progress to cirrhosis. There are metabolic risk factors common to both NAFLD and cardiovascular disease, so patients with NASH have an increased risk of liver-related and cardiovascular death. Management of patients with NAFLD depends largely on the stage of disease, emphasising the importance of careful risk stratification. There are four main areas to focus on when thinking about management strategies in NAFLD: lifestyle modification, targeting the components of the metabolic syndrome, liver-directed pharmacotherapy for high risk patients and managing the complications of cirrhosis.
    10/2014; 5(4):277-286. DOI:10.1136/flgastro-2013-100404
  • Source
    • "After the storm of controversy and bad press, it is unlikely this rosiglitazone will ever be widely used again, as there is no unique benefit for this drug compared to pioglitazone—except perhaps for bladder cancer risk (see below). Furthermore, a similar meta-analysis for pioglitazone showed no excess cardiovascular mortality, and in fact an 18% decrease in cardiovascular endpoints (Lincoff et al., 2007). An large observational cohort of U.S. Medicare patients showed that rosiglitazone has cardiovascular harm compared to pioglitazone (Graham et al., 2010), while a UK cohort study showed that pioglitazone but not rosiglitazone reduced all-cause "
    [Show abstract] [Hide abstract]
    ABSTRACT: Type 2 diabetes is caused by insulin resistance coupled with an inability to produce enough insulin to control blood glucose, and thiazolidinediones (TZDs) are the only current antidiabetic agents that function primarily by increasing insulin sensitivity. However, despite clear benefits in glycemic control, this class of drugs has recently fallen into disuse due to concerns over side effects and adverse events. Here we review the clinical data and attempt to balance the benefits and risks of TZD therapy. We also examine potential mechanisms of action for the beneficial and harmful effects of TZDs, mainly via agonism of the nuclear receptor PPARγ. Based on critical appraisal of both preclinical and clinical studies, we discuss the prospect of harnessing the insulin sensitizing effects of PPARγ for more effective, safe, and potentially personalized treatments of type 2 diabetes.
    Cell Metabolism 09/2014; 20(4). DOI:10.1016/j.cmet.2014.08.005 · 17.57 Impact Factor
Show more